Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

ClinicalTrials.gov ID: NCT00710580

Public ClinicalTrials.gov record NCT00710580. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

Study identification

NCT ID
NCT00710580
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Enrollment
350 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2008
Primary completion
Mar 31, 2009
Completion
Mar 31, 2009
Last update posted
Jan 17, 2013

2008 – 2009

United States locations

U.S. sites
42
U.S. states
22
U.S. cities
38
Facility City State ZIP Site status
Site Reference ID/Investigator# 9984 Birmingham Alabama 35205
Site Reference ID/Investigator# 10605 Birmingham Alabama 35233
Site Reference ID/Investigator# 10001 Scottsdale Arizona 85251
Site Reference ID/Investigator# 10502 Little Rock Arkansas 72205
Site Reference ID/Investigator# 9985 Bakersfield California 93309
Site Reference ID/Investigator# 10661 Irvine California 92697
Site Reference ID/Investigator# 14701 Los Angeles California 90045
Site Reference ID/Investigator# 9785 San Diego California 92123
Site Reference ID/Investigator# 10662 Santa Monica California 90404
Site Reference ID/Investigator# 10642 Vallejo California 94589
Site Reference ID/Investigator# 10263 New Haven Connecticut 06511
Site Reference ID/Investigator# 10503 Jacksonville Florida 32204
Site Reference ID/Investigator# 10266 Miami Florida 33144
Site Reference ID/Investigator# 9901 Miami Florida 33173
Site Reference ID/Investigator# 10501 West Palm Beach Florida 33407
Site Reference ID/Investigator# 15201 Alpharetta Georgia 30022
Site Reference ID/Investigator# 10762 Atlanta Georgia 30327
Site Reference ID/Investigator# 10262 Newnan Georgia 30263
Site Reference ID/Investigator# 9789 Snellville Georgia 30078
Site Reference ID/Investigator# 10666 Maywood Illinois 60153
Site Reference ID/Investigator# 15142 Plainfield Indiana 46168
Site Reference ID/Investigator# 10265 Louisville Kentucky 40202
Site Reference ID/Investigator# 15750 Owensboro Kentucky 42303
Site Reference ID/Investigator# 9790 Owensboro Kentucky 42303
Site Reference ID/Investigator# 9788 Fort Gratiot Michigan 48059
Site Reference ID/Investigator# 10604 Grand Blanc Michigan 48439
Site Reference ID/Investigator# 10541 Fridley Minnesota 55432
Site Reference ID/Investigator# 10641 St Louis Missouri 63110
Site Reference ID/Investigator# 10606 Omaha Nebraska 68131
Site Reference ID/Investigator# 10644 Omaha Nebraska 68144
Site Reference ID/Investigator# 9786 Berlin New Jersey 08009
Site Reference ID/Investigator# 10241 New York New York 10016
Site Reference ID/Investigator# 9787 Rochester New York 14623
Site Reference ID/Investigator# 9902 Hickory North Carolina 28601
Site Reference ID/Investigator# 10581 Wilmington North Carolina 28401
Site Reference ID/Investigator# 10504 Dayton Ohio 45408
Site Reference ID/Investigator# 10643 Knoxville Tennessee 37934
Site Reference ID/Investigator# 9981 Dallas Texas 75230
Site Reference ID/Investigator# 10264 San Antonio Texas 78229
Site Reference ID/Investigator# 9982 Webster Texas 77598
Site Reference ID/Investigator# 10182 Seattle Washington 98101
Site Reference ID/Investigator# 10321 Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00710580, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2013 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00710580 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →